[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"essential-tremor-movement-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:essential-tremor-movement-disorders":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,77,98],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100625885","analysis-of-cutaneous-phosphorylated-alpha-synuclein-to-identify-patients-at-risk-of-progressing-from-essential-tremor-to-parkinsons-disease-100625885",false,"NCT07428447","Analysis of Cutaneous Phosphorylated Alpha-Synuclein to Identify Patients at Risk of Progressing From Essential Tremor to Parkinson's Disease","Syn-T","Inclusion Criteria:\n\n* Age 50-85 years old\n* Diagnosis of ET as defined by the 2018 MDS Task force paper \"1) isolated tremor syndrome of bilateral upper limb action tremor 2) at least 3 years' duration 3) with or without tremor in other locations (e.g., head, voice, or lower limbs) 4) absence of other neurological signs, such as dystonia, ataxia, or parkinsonism.\" OR\n* Diagnosis of ET-Plus as stated by the 2018 MDS Task force paper, \"Tremor with the characteristics of ET and additional neurological signs of uncertain significance such as impaired tandem gait, questionable dystonic posturing, memory impairment, or other mild neurologic signs of unknown significance that do not suffice to make an additional syndrome classification or diagnosis. ET with tremor at rest should be classified here.\"\n* Willing to participate in all study procedures\n* Able and willing to provide written informed consent\n\nExclusion Criteria:\n\n* Under age 50, Over age 85\n* Clinical evidence of severe peripheral vascular disease\n* Clinically active coronary artery or cerebrovascular disease\n* Participant is currently on anticoagulant or dual anti-platelet therapy\n* Alcoholism\n* Allergic reaction to local anesthesia\n* History of or increased risk for impaired wound healing, scarring, or keloid formation\n* Diagnosis of ET or ET-Plus that is clinically determined to likely be secondary to brain injury or vascular compromise\n* History of other neurodegenerative disorder or evidence of neurological co-pathology\n* Abnormal DaTscan\n* Participant is currently receiving treatment with carbidopa-levodopa for PD\n* Isolated focal tremors (head, voice)\n* Task-specific tremor (e.g., primary writing tremor)\n* Position-specific tremors that does not otherwise meet clinical diagnostic criteria for ET\n* Sudden onset and step-wise deterioration","ALL","50 Years","85 Years",{"count":20,"type":21},300,"ESTIMATED","OBSERVATIONAL","Background and Rationale Essential tremor (ET) affects over 6 million Americans and approximately 5% of adults over age 60. Patients with ET have a 10-20 times higher risk of developing Parkinson's disease (PD) compared to age-matched populations, with approximately 1% converting to PD annually. Post-mortem studies reveal Lewy body pathology in some ET patients, suggesting a subset may have prodromal PD. Current diagnostic tools (DaTscan, SYNTap) are either insufficiently sensitive for early disease, too expensive, or too invasive for routine screening. The Syn-One Test offers a minimally invasive approach to detect phosphorylated α-synuclein (P-SYN) pathology in skin biopsies.\n\nPrimary Objectives\n\n1. Identify which ET patients have P-SYN pathology indicative of prodromal PD\n2. Predict which patients are most likely to phenoconvert to PD",[25,26,27],"Essential Tremor, Movement Disorders","Essential Tremor","Essential Tremor-plus",[29,30],"skin biopsy","Syn-One","RECRUITING","2026-07-01",{"date":34,"type":35},"2026-07-02","ACTUAL",{"date":37,"type":35},"2026-02-18",{"date":39,"type":21},"2029-02",{"name":41,"class":42},"CND Life Sciences","OTHER",2,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":51,"sex":16,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100597273","long-term-brain-stimulation-of-the-motor-ventral-thalamus-vopvim-to-improve-motor-function-100597273","NCT07056348","Long-term Brain Stimulation of the Motor Ventral Thalamus (VOP\u002FVIM) to Improve Motor Function","Chronic Stimulation of the Motor Ventral Thalamus (VOP\u002FVIM) for Motor Control in Humans","Inclusion Criteria:\n\n* Movement disorder patients ≥18 years of age and \\\u003C 80 years of age, who will be implanted with DBS for treatment of motor symptoms.\n* Subject has provided written informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization, where applicable, prior to any study-related procedures.\n\nExclusion Criteria:\n\n* History of seizure disorders\n* Vasovagal response history and loss of consciousness history\n* Severe behavioral or cognitive problems that preclude participation in the study, in the opinion of the investigator would impact participation in the study.\n* Any serious disease or disorder (e.g. cancer, severe cardiac or respiratory disease, neurological conditions other than current movement disorder) or cognitive impairments that could impair ability to participate in this study.\n* Females who are pregnant or breastfeeding.",true,"18 Years","80 Years",{"count":55,"type":21},60,"INTERVENTIONAL",[58],"NA","This study aims to recruit patients already implanted with Deep Brain Stimulation (DBS) for movement disorders to complete tasks assessing parameters of motor output, speech, and swallowing functions, both with and without stimulation. DBS parameters would be adjusted prior to motor testing. Patients would then participate in multiple sessions performing contralateral upper extremity movement tasks measuring movement speed, grip strength, and strength modulation, facial movement, swallowing, and speech tasks.",[61,62,63,64,65,25,66],"Traumatic Brain Injury","Stroke","Brain Disease","Movement Disorders (Incl Parkinsonism)","Central Nervous System Disease","Essential Tremor of Voice","2025-12-08",{"date":69,"type":35},"2025-12-16",{"date":71,"type":35},"2022-05-10",{"date":73,"type":21},"2030-12-31",{"name":75,"class":42},"Jorge Gonzalez-Martinez",1,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":16,"minAge":52,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":56,"phases":86,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":97,"locationsCount":76},"100597274","stimulating-specific-brain-areas-vopvim-with-electricity-to-improve-movement-and-muscle-control-100597274","NCT07056361","Stimulating Specific Brain Areas (VOP\u002FVIM) With Electricity to Improve Movement and Muscle Control","VOP\u002FVIM Direct Electrical Stimulation Increases Motor Cortex Excitability and Motor Output","Inclusion Criteria:\n\n* Essential tremor patients who are scheduled to undergo deep brain stimulation surgery at UPMC Presbyterian with asymmetric essential tremor symptoms will be included, with the tested limb corresponding to the least affected arm to better approximate normal function. These patients are implanted bilaterally regardless of symptom laterality, as the natural history of essential tremor indicates eventual bilateral symptoms.\n* Parkinson's Disease patients who are scheduled to undergo deep brain stimulation surgery at UPMC Presbyterian with a history of Parkinson's Disease will also be recruited for intra-operative stimulation of their STN-targeted implants, to assess if VIM\u002FVOP has high specificity for improving motor output.\n\nConfirmation that subjects' terms of insurance coverage for their standard of care procedure will not be altered by study enrollment.\n\nExclusion Criteria:\n\n* Patients will be excluded from the study if there is any seizure history, to avoid the increased epileptogenic risk of intraoperative stimulation.\n* Patients with significant bilateral tremor that precludes completion of motor tasks.","75 Years",{"count":55,"type":21},[58],"In this study the investigators aim to enroll patients scheduled to undergo deep brain stimulation (DBS) implantation for movement disorders for intra-operative testing. In addition to standard-of-care surgical procedure to implant deep brain stimulation electrode leads, participants will also be stimulated and recorded from cortical areas by a temporary strip electrode (1X6) in the subdural space. The electrodes will be connected to external stimulators and a series of experiments will be performed to assess effects of the DBS on movement quality and electrophysiology measures. Results of this study will elucidate the biological mechanisms related to deep brain stimulation in modulating motor and speech function in patients with abnormal movement disorders.",[64,62,61,89,90,25],"Brain Diseases","Parkinson Disease","2025-11-05",{"date":93,"type":35},"2025-11-10",{"date":95,"type":35},"2022-12-16",{"date":73,"type":21},{"name":75,"class":42},{"id":99,"slug":100,"hasResults":11,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":4,"eligibilityCriteria":104,"healthyVolunteers":11,"sex":16,"minAge":105,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":108,"conditions":109,"keywords":110,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":120,"completionDateStruct":122,"leadSponsor":124,"locationsCount":76},"100609259","analysis-of-clinical-outcomes-in-patients-undergoing-magnetic-resonance-guided-focused-ultrasound-for-medication-refractory-tremor-100609259","NCT07212244","Analysis of Clinical Outcomes in Patients Undergoing Magnetic Resonance-Guided Focused Ultrasound for Medication-Refractory Tremor","A Prospective, Long-term Analysis of Clinical Outcomes in Patients Undergoing Magnetic Resonance-Guided Focused Ultrasound for Medication-Refractory Tremor","Inclusion Criteria:\n\n1. Aged 22 years or older\n2. Able and willing to give consent and to attend all visits\n3. Diagnosed with essential tremor that is refractory to at least two first-line tremor medications\n4. Confirmed to have moderate-to-severe hand tremor by the MRI guided Focused Ultrasound (MRgFUS) neurology team\n5. Deemed suitable surgical candidates (decision-to-treat) by the MRgFUS neurosurgical team\n\nExclusion Criteria:\n\n1. Patients with standard contraindications to MRI such as non-MRI compatible implants or devices\n2. Patients deemed clinically unfit to undergo MRgFUS thalamotomy due to health status including (but not limited to) pregnancy, advanced kidney disease, unstable cardiac status, severe hypertension, cerebrovascular disease, brain tumour, pulmonary disorders\n3. Receiving anti-coagulants or drugs known to increase risk of hemorrhage within 2 weeks of MRgFUS procedure","22 Years",{"count":107,"type":21},240,"The goal of this observational study is to evaluate the long-term efficacy and safety of MR-guided focused ultrasound (MRgFUS) thalamotomy in patients with medication-refractory essential tremor.\n\nThe main questions it aims to answer are:\n\n1. Does MRgFUS thalamotomy provide sustained reduction in tremor severity over 3 years?\n2. What are the long-term neurological and quality-of-life outcomes associated with this procedure?\n\nParticipants will:\n\n* Undergo MRgFUS thalamotomy as part of standard of care at Sunnybrook Health Sciences Centre.\n* Be followed prospectively for a minimum of 3 years with scheduled assessments including:\n\n  1. Clinical Rating Scale for Tremor (CRST)\n  2. Neurological exams and adverse event monitoring\n  3. Quality of Life in Essential Tremor (QUEST) questionnaire\n  4. Scale for the Assessment and Rating of Ataxia (SARA)\n  5. MRI imaging and neuropsychological testing",[26,25],[111,112,113,114,115,116],"Focused Ultrasound","Thalamotomy","Hand tremor","MRI-guided focused ultrasound (MRgFUS)","Primidone","Propranolol","2025-09-30",{"date":119,"type":35},"2025-10-08",{"date":121,"type":21},"2025-10",{"date":123,"type":21},"2032-09",{"name":125,"class":42},"Sunnybrook Health Sciences Centre"]